Fierce Biotech reports that Sanofi and Regeneron's drug aflibercept (VEGF trap) for thetreatment of non-small cell lung cancer, used in combination with docataxel, failed to meet its endpoint, extending overall survival, in its latest phase III trial. It did improve progression-free survival though. Side effects were significant and 27.2 percent of the treatment group had to leave the trial. Like most of these failures, the sponsors say they will take a closer look at the data to determine if they can proceed or will stop. 
Posted by Bruce Lehr March 13th 2011.
Comments